Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
A5324 is a 96-week, randomized, double-blind, placebo-controlled clinical trial involving 191 participants with HIV and neurocognitive impairment. The trial, conducted by the ACTG Statistical and Data Analysis Center, compared three antiretroviral intensification regimens and measured outcomes including cognitive function, depressive symptoms, and body mass index. The dataset includes results from participant screening and the 96-week study period.
License is CC-BY-NC-4.0, restricting commercial use. Files include PDF, DOCUMENT, and SAS syntax formats, which may require specific tools for analysis.